title: Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.
abstract: OBJECTIVE
  Treatment of multiple sclerosis patients with glatiramer acetate has been demonstrated a beneficial effect on disease activity. The objective of this prospective naturalistic study was to evaluate the impact of glatiramer acetate on fatigue and work absenteeism.
  
  
  METHODS
  291 treatment-naïve patients with relapsing remitting multiple sclerosis were included and treated with glatiramer acetate for twelve months. Relapse rates, disability, fatigue symptoms, days of absence from work and adverse events were monitored. Fatigue was measured with the MFIS scale and with a visual analogue scale.
  
  
  RESULTS
  Total MFIS scores decreased by 7.6 +/- 16.4 from 34.6 to 27.0 (p < or = 0.001). Significant reductions were observed on all three subscales of the MFIS. Fatigue symptoms, assessed using a visual analogue scale, decreased by 1.04 +/- 2.88 cm from 4.47 cm to 3.43 cm (p < or = 0.001). The proportion of patients absent from work at least once was reduced by a factor of two from 65.1% to 30.1% (p < or = 0.001). Tolerance to treatment was rated as very good or good in 78.3% of patients. Adverse effects, most frequently local injection site reactions, were reported in 15.1% of patients.
  
  
  CONCLUSIONS
  Treatment with glatiramer acetate was associated with a significant improvement in fatigue symptoms and a marked reduction in absence from work. Treatment was well-tolerated. Such benefits are of relevance to overall patient well-being.
authors.affiliation: MS Center, Neurological University Clinic, Technical University of Dresden, Dresden, Germany. Tjalf.Ziemssen@uniklinikum-dresden.de
authors.forename: Tjalf
authors.initials: T
authors.lastname: Ziemssen
authors.forename: Josef
authors.initials: J
authors.lastname: Hoffman
authors.forename: Rainer
authors.initials: R
authors.lastname: Apfel
authors.forename: Simone
authors.initials: S
authors.lastname: Kern
mesh_terms: D000041:Absenteeism; D000328:Adult; D004185:Disability Evaluation; D005221:Fatigue / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005858:Germany; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy*; D019370:Observation; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate
references.citation: CNS Drugs. 2003;17(4):225-34
references.pmid: 12665396
references.citation: Acta Neurol Scand. 2004 Jul;110(1):6-13
references.pmid: 15180801
references.citation: Drug Saf. 2001;24(13):979-90
references.pmid: 11735654
references.citation: Parkinsonism Relat Disord. 2007 Aug;13(6):323-32
references.pmid: 17349813
references.citation: Mult Scler. 2005 Oct;11(5):602-9
references.pmid: 16193900
references.citation: Drugs. 2004;64(12):1295-304
references.pmid: 15200345
references.citation: J Neurol Sci. 2002 Dec 15;205(1):51-8
references.pmid: 12409184
references.citation: Arch Phys Med Rehabil. 1984 Mar;65(3):135-8
references.pmid: 6703889
references.citation: Arch Neurol. 2004 Feb;61(2):201-7
references.pmid: 14967766
references.citation: J Neurol Sci. 2007 Dec 15;263(1-2):15-9
references.pmid: 17673234
references.citation: J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):34-9
references.pmid: 16361589
references.citation: J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1045-7
references.pmid: 15201369
references.citation: J Rehabil Res Dev. 2002 Mar-Apr;39(2):211-24
references.pmid: 12051465
references.citation: J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):179-83
references.pmid: 11796766
references.citation: Curr Treat Options Neurol. 2003 Jan;5(1):35-54
references.pmid: 12521562
references.citation: Brain. 2002 Nov;125(Pt 11):2381-91
references.pmid: 12390966
references.citation: Axone. 1991 Sep;13(1):16-7, 20-2
references.pmid: 1888670
references.citation: Neurology. 2005 Apr 12;64(7):1139-43
references.pmid: 15824337
references.citation: Curr Opin Neurol. 1996 Dec;9(6):456-60
references.pmid: 9007405
references.citation: Mult Scler. 2001 Oct;7(5):340-4
references.pmid: 11724451
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002818
references.pmid: 17253480
references.citation: Hum Brain Mapp. 2007 May;28(5):373-82
references.pmid: 16933299
references.citation: Work. 2006;27(2):143-51
references.pmid: 16971761
references.citation: Baillieres Clin Neurol. 1997 Oct;6(3):429-45
references.pmid: 10101582
references.citation: Neurology. 1983 Nov;33(11):1444-52
references.pmid: 6685237
references.citation: Ann Neurol. 2001 Jul;50(1):121-7
references.pmid: 11456302
references.citation: J Neurol. 2001 Mar;248(3):174-9
references.pmid: 11355149
references.citation: Mult Scler. 2004 Apr;10(2):165-9
references.pmid: 15124762
references.citation: Mult Scler. 2005 Apr;11(2):198-202
references.pmid: 15794395
references.citation: J Neuroimaging. 2008 Jul;18(3):314-9
references.pmid: 18304034
references.citation: Arch Neurol. 1996 Jul;53(7):642-9
references.pmid: 8929171
references.citation: Can J Neurol Sci. 1994 Feb;21(1):9-14
references.pmid: 8180914
references.citation: Mult Scler. 2002 Dec;8(6):523-6
references.pmid: 12474995
references.citation: Mult Scler. 2008 Jan;14(1):6-21
references.pmid: 17881389